DaVita DVA · USD
Health Care · Health Care Providers & Services · US listing · 🇺🇸 United States
S&P 500
185.54
-3.04%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About DaVita
From its filings with the US Securities and Exchange Commission
DaVita is based in Denver, Colorado and is incorporated in Delaware. Its shares trade on NYSE under the ticker DVA. It is a member of the S&P 500. The SEC classifies its business as misc health & allied services, nec. In the fiscal year to 31 December 2025, it reported revenue of $13.64bn and net income of $746.8m. At that date it held total assets of $17.48bn and shareholders' equity of −$651.1m. By business, U S Dialysis brought in 86.0% of revenue, followed by Other - Ancillary services at 14.0%.
DaVita is a leading healthcare provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, we have been a leader in clinical quality and innovation for more than 25 years. We care for patients at every stage and setting along their kidney health journey–from slowing the progression of kidney disease to helping support transplantation. This includes ensuring they are supported at home, in our dialysis centers, in the hospital and in skilled nursing facilities. In our unwavering pursuit of a healthier tomorrow, we strive to reimagine what high quality care looks like: more preventative, better integrated, improved outcomes at the lowest total cost, and personalized at scale to deliver a better tomorrow regardless of location, insurance status or other factors. Our caring culture fuels our continuous drive toward achieving our mission to be the provider, partner and employer of choice.
There are five stages of chronic kidney disease (CKD). These stages are generally based on how well the kidneys work to filter waste and extra fluid out of the blood–with higher stages of CKD corresponding to progressing levels of kidney disease. Stage 1 CKD is the closest to healthy kidney function. Stage 5 CKD indicates that a patient has severe kidney damage.
Quoted from its 10-K, filed 11 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 31 Oct 1995
- Employees
- 78,000
- Website
- davita.com ↗
- Head office
- 2000 16TH STREET, DENVER, CO, 80202
- Incorporated in
- DE
- Classification
- Services-Misc Health & Allied Services, NEC
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Ms. Pamela ArwayIndependent Chair of the Board$499,708
- Mr. Javier RodriguezChief Executive Officer, Director, since 2000$21.8m
- Mr. Joel AckermanChief Financial Officer, Treasurer$6.3m
- Mr. Christopher BerryChief Accounting Officer
- Mr. James HeartyChief Compliance Officer$2.3m
- Mr. David MaughanChief Operating Officer - Davita Kidney Care$4.9m
- Ms. Kathleen WatersChief Legal and Public Affairs Officer$4.7m
- Ms. Barbara DesoerIndependent Director$384,708
- Mr. Jason HollarIndependent Director$372,208
- Dr. Gregory MooreIndependent Director$377,208
- Mr. Dennis PullinIndependent Director$172,538
- Mr. Adam SchechterIndependent Director$334,708
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 79
- Environment
- 82
- Social
- 65
- Governance
- 89
- Direct emissions (scope 1)
- 59,569 t
- Energy emissions (scope 2)
- 206,214 t
- Value chain emissions (scope 3)
- 705,383 t
- Women in the workforce
- 78%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Industry Leadership: DaVita Inc is one of the leading providers of kidney dialysis services in the healthcare industry.
- Extensive Network: The company operates a vast network of dialysis centers across the United States and internationally.
- High-Quality Care: DaVita is known for providing exceptional patient care and achieving positive patient outcomes.
Weaknesses
- Legal and Regulatory Risks: The healthcare industry is subject to strict regulations, which may pose challenges to DaVita's operations.
- Dependence on Medicare and Medicaid: A significant portion of DaVita's revenue comes from government-funded healthcare programs, making it vulnerable to changes in reimbursement policies.
- Vulnerability to Litigation: DaVita has faced legal issues in the past, which can impact its reputation and financial performance.
Opportunities
- Growing Demand for Dialysis Services: The increasing prevalence of chronic kidney disease presents an opportunity for DaVita to expand its customer base.
- International Expansion: DaVita can explore new markets and expand its presence in countries with a significant need for dialysis services.
- Technological Advancements: Embracing technological innovations in healthcare can enhance DaVita's operations and improve patient care.
Threats
- Competitive Landscape: Other major players in the dialysis services industry pose a threat to DaVita's market share and profitability.
- Pricing Pressure: Pricing pressures from insurance providers and government payers can impact DaVita's financial performance.
- Economic Downturn: During economic downturns, individuals may delay or forgo non-essential medical treatments, which could affect DaVita's revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.